Ramipril News and Research

RSS

Uromodulin levels linked to kidney failure risk

Prior studies of uromodulin, the most abundant protein in urine, and kidney disease have focused primarily on urinary uromodulin levels.

20 Sep 2023

Insights from a global study: The association between dietary patterns, cardiovascular diseases, and deaths

Researchers develop a healthy diet score linked to health outcomes with global applicability using the Prospective Urban Rural Epidemiology study data.

20 Jul 2023

Three-drug medication effective in preventing recurrent cardiovascular events after a heart attack

A three-drug medication known as a "polypill," developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.

26 Aug 2022

Gut bacteria can reduce the effectiveness of certain blood pressure drugs

A new study from The University of Toledo College of Medicine and Life Sciences has shown gut bacteria can reduce the effectiveness of certain blood pressure drugs.

26 May 2022

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

Combination of polypill and aspirin can reduce cardiovascular events by up to 40%

Heart attacks, strokes and other cardiovascular incidents can be cut by 20 to 40 per cent through use of a polypill which combines three blood pressure medications and a lipid lowering medication taken alone or with aspirin.

16 Nov 2020

Polypill plus aspirin and polypill alone reduced cardiovascular disease risk

A single, daily pill combining blood pressure and cholesterol medications, along with the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking research presented today in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2020.

15 Nov 2020

Common high blood pressure medications do not increase risk of depression

None of the 41 most common high blood pressure medications increased the risk of depression, while nine medications appeared to lower it, according to a study from Denmark, published today in Hypertension, an American Heart Association journal.

24 Aug 2020

UTHealth physicians investigate blood pressure drug's effect on improving COVID-19 outcomes

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston.

14 Jul 2020

New clinical trial to assess whether hypertension drug may reduce COVID-19 severity

Researchers at University of California San Diego School of Medicine have launched a clinical trial to investigate whether a drug approved for treating high blood pressure, heart failure and diabetic kidney disease might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.

30 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

Study suggests proteinuria lowering as important target in managing pediatric CKD

In a study of children with chronic kidney disease, blood pressure medications reduced protein excretion in the urine, which was linked with a lower risk of disease progression.

22 Jun 2018

New study predicts outcomes of CV patients using polypill intervention

A new study published in the journal BMJ Open (May 2015) has demonstrated that the improved treatment adherence achievable using a fixed-dose combination polypill (atorvastatin, ramipril and low-dose aspirin) to prevent recurring myocardial infarction, can avoid up to 15% more fatal and non-fatal CV events, conferring potential savings to healthcare systems.

19 Jun 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain.

3 Sep 2014

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US.

1 Sep 2014

Ramipril puts spring in step of patients with intermittent claudication

Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial.

6 Feb 2013

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.